Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer
Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.
Merck's Oncology Engine Is Still Accelerating
I continue to believe that Merck & Co., Inc. has an attractive risk/reward profile. Ten days ago, on June 12, the FDA approved both Keytruda and Keytruda Qlex in combination with Welireg for the treatment of a type of kidney cancer called earlier-stage ccRCC. Overall, this "trio" generated $8.23 billion in sales for Merck in Q1, up 12.1% year-over-year.
Merck's bowel disease drug meets main goal in late-stage trial
Merck said on Monday its drug met the main goal in a late-stage trial testing it in patients with a type of inflammatory bowel disease.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who face a higher risk of catching the bacterial disease due to chronic health conditions.
